Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Product liability bill

This article was originally published in The Tan Sheet

Executive Summary

In a Nov. 5 letter to senators and members of the House Commerce Subcommittee, NDMA urged support for product liability legislation (S 687) cosponsored by Sens. Jay Rockefeller (D- W.Va.), Slade Gorton (R-Wash.) and others. Characterizing the bill as a "fair" and "responsible" measure, NDMA said that S 687 meets the need for a stable climate in which our members can produce new, safe and effective" OTCs at competitive prices." The bill cleared the Senate Commerce Committee by a 16-4 vote at a Nov. 9 markup and will be referred to the Judiciary Committee and then to the Senate floor. Supporters of S 687 expect consideration by the full Senate in early 1994. As in previous years, the bill contains a provision to protect from punitive damages manufacturers of products considered safe and effective by FDA. No action has been taken on House companion measures HR 1910 and HR 1954.

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

People In Brief

Perrigo promotes in pricing, planning

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS082175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel